QUANTITATION OF METHYLATION LOAD OF UCHL1 GENE PROMOTER METHYLATION IN PANCREATIC CANCER

被引：0
|
作者：
Singh, Nidhi
Rashid, Sumaira
Rashid, Safoora
Gupta, Surabhi
Saraya, Anoop
机构：
来源：
GASTROENTEROLOGY | 2018年 / 154卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Tu1363
引用
收藏
页码：S944 / S944
页数：1
相关论文
共 50 条
  • [1] QUANTITATION OF METHYLATION LOAD OF TUMOR SUPPRESSOR GENE PROMOTER METHYLATION IN PANCREATIC CANCER
    Singh, Nidhi
    Gupta, Surabhi
    Rashid, Sumaira
    Rashid, Safoora
    Dash, Nihar R.
    Saraya, Anoop
    GASTROENTEROLOGY, 2019, 156 (06) : S1176 - S1176
  • [2] The Diagnosis Value of Promoter Methylation of UCHL1 in the Serum for Progression of Gastric Cancer
    Wang, Gongping
    Zhang, Wei
    Zhou, Bo
    Jin, Canhui
    Wang, Zengfang
    Yang, Yantong
    Wang, Zhenzhen
    Chen, Ye
    Feng, Xiaoshan
    BIOMED RESEARCH INTERNATIONAL, 2015, 2015
  • [3] Methylation of UCHL1 as a prognostic biomarker for cholangiocarcinoma
    Nanok, Chaiyachet
    Leelayuwat, Chanvit
    Jearanaikoon, Patcharee
    Proungvitaya, Siriporn
    Limpaiboon, Temduang
    CANCER SCIENCE, 2018, 109 : 243 - 243
  • [4] Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation
    Ummanni, Ramesh
    Jost, Edgar
    Braig, Melanie
    Lohmann, Frithjof
    Mundt, Frederike
    Barett, Christine
    Schlomm, Thorsten
    Sauter, Guido
    Senff, Tina
    Bokemeyer, Carsten
    Sueltmann, Holger
    Meyer-Schwesinger, Catherine
    Bruemmendorf, Tim H.
    Balabanov, Stefan
    MOLECULAR CANCER, 2011, 10
  • [5] Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation
    Ramesh Ummanni
    Edgar Jost
    Melanie Braig
    Frithjof Lohmann
    Frederike Mundt
    Christine Barett
    Thorsten Schlomm
    Guido Sauter
    Tina Senff
    Carsten Bokemeyer
    Holger Sültmann
    Catherine Meyer-Schwesinger
    Tim H Brümmendorf
    Stefan Balabanov
    Molecular Cancer, 10
  • [6] FAT1 GENE PROMOTER METHYLATION: CLINICAL SIGNIFICANCE IN PANCREATIC CANCER
    Singh, Nidhi
    Khan, Imteyaz A.
    Rashid, Safoora
    Rashid, Sumaira
    Sharma, Sanchit
    Gunjan, Deepak
    Dash, Nihar R.
    Yadav, Rajni
    Gupta, Surabhi
    Saraya, Anoop
    GASTROENTEROLOGY, 2021, 160 (06) : S591 - S591
  • [7] QUANTITATIVE DETECTION OF SPARC GENE PROMOTER METHYLATION IN PANCREATIC CANCER
    Singh, Nidhi
    Rashid, Sumaira
    Rashid, Safoora
    Gupta, Surabhi
    Saraya, Anoop
    GASTROENTEROLOGY, 2017, 152 (05) : S492 - S493
  • [8] Aberrant methylation of HTATIP2 and UCHL1 as a predictive biomarker for cholangiocarcinoma
    Nanok, Chaiyachet
    Jearanaikoon, Patcharee
    Proungvitaya, Siriporn
    Limpaiboon, Temduang
    MOLECULAR MEDICINE REPORTS, 2018, 17 (03) : 4145 - 4153
  • [9] Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1
    Heitzer, Ellen
    Artl, Monika
    Filipits, Martin
    Resel, Margit
    Graf, Ricarda
    Weissenbacher, Bettina
    Lax, Sigurd
    Gnant, Michael
    Wrba, Fritz
    Greil, Richard
    Dietze, Otto
    Hofbauer, Friedrich
    Boehm, Gerhard
    Hoefler, Gerald
    Samonigg, Hellmut
    Schaberl-Moser, Renate
    Balic, Marija
    Dandachi, Nadia
    MODERN PATHOLOGY, 2014, 27 (06) : 906 - 915
  • [10] Methylation of the SPARC gene promoter and its clinical implication in pancreatic cancer
    Gao, Jun
    Song, Jian
    Huang, Haojie
    Li, Zhaoshen
    Du, Yiqi
    Cao, Jia
    Li, Minghui
    Lv, Shunli
    Lin, Han
    Gong, Yanfang
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2010, 29
12345